{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:56:16Z","timestamp":1783482976941,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40123-022-00501-2","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T12:02:57Z","timestamp":1650715377000},"page":"1231-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03287635","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Melissa","family":"Toyos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Toyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jodoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bunch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"issue":"6","key":"501_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4274\/tjo.69320","volume":"48","author":"C Simsek","year":"2018","unstructured":"Simsek C, Dogru M, Kojima T, Tsubota K. Current management and treatment of dry eye disease. Turk J Ophthalmol. 2018;48(6):309\u201313.","journal-title":"Turk J Ophthalmol"},{"issue":"3","key":"501_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365.","journal-title":"Ocul Surf"},{"issue":"3","key":"501_CR3","first-page":"192","volume":"6","author":"MA Javadi","year":"2011","unstructured":"Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192\u20138.","journal-title":"J Ophthalmic Vis Res"},{"key":"501_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"501_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40123-020-00308-z","volume":"9","author":"MA Verjee","year":"2020","unstructured":"Verjee MA, Brissette AR, Starr CE. Dry eye disease: early recognition with guidance on management and treatment for primary care family physicians. Ophthalmol Ther. 2020;9(4):877\u201388.","journal-title":"Ophthalmol Ther"},{"key":"501_CR6","doi-asserted-by":"publisher","first-page":"18619","DOI":"10.1038\/srep18619","volume":"5","author":"Y Ru","year":"2015","unstructured":"Ru Y, Huang Y, Liu H, et al. alpha-Melanocyte-stimulating hormone ameliorates ocular surface dysfunctions and lesions in a scopolamine-induced dry eye model via PKA-CREB and MEK-Erk pathways. Sci Rep. 2015;5:18619.","journal-title":"Sci Rep"},{"key":"501_CR7","unstructured":"Mallinckrodt Pharmaceuticals. Acthar gel. Package insert. 2021. https:\/\/www.actharhcp.com. Accessed 20 May 2020"},{"issue":"2","key":"501_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40744-020-00199-3","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7(2):327\u201344.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"501_CR9","doi-asserted-by":"publisher","first-page":"e000240","DOI":"10.1136\/lupus-2017-000240","volume":"4","author":"RA Furie","year":"2017","unstructured":"Furie RA, Mitrane M, Zhao E, Becker PM. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study. Lupus Sci Med. 2017;4(1):e000240.","journal-title":"Lupus Sci Med."},{"issue":"4","key":"501_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40744-020-00236-1","volume":"7","author":"AD Askanase","year":"2020","unstructured":"Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol Ther. 2020;7(4):893\u2013908.","journal-title":"Rheumatol Ther"},{"key":"501_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10799893.2020.1859533","volume":"20","author":"YJ Huang","year":"2020","unstructured":"Huang YJ, Galen K, Zweifel B, Brooks LR, Wright AD. Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists. J Recept Signal Transduct Res. 2020;20:1\u20139.","journal-title":"J Recept Signal Transduct Res"},{"issue":"1","key":"501_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cei.13089","volume":"192","author":"AL Benko","year":"2018","unstructured":"Benko AL, McAloose CA, Becker PM, et al. Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids. Clin Exp Immunol. 2018;192(1):68\u201381.","journal-title":"Clin Exp Immunol"},{"key":"501_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13075-015-0823-y","volume":"17","author":"NJ Olsen","year":"2015","unstructured":"Olsen NJ, Decker DA, Higgins P, et al. Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro. Arthritis Res Ther. 2015;17:300.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"501_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/08916934.2014.984836","volume":"48","author":"MF Cusick","year":"2015","unstructured":"Cusick MF, Libbey JE, Oh L, Jordan S, Fujinami RS. Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis. Autoimmunity. 2015;48(4):222\u201330.","journal-title":"Autoimmunity"},{"key":"501_CR15","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S175065","volume":"12","author":"J Tauber","year":"2018","unstructured":"Tauber J, Schechter BA, Bacharach J, et al. A phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"501_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539\u201374.","journal-title":"Ocul Surf"},{"issue":"5","key":"501_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.eye.6702295","volume":"21","author":"PJ Murphy","year":"2007","unstructured":"Murphy PJ, Lau JS, Sim MM, Woods RL. How red is a white eye? Clinical grading of normal conjunctival hyperaemia. Eye. 2007;21(5):633\u20138.","journal-title":"Eye"},{"issue":"79\u201380","key":"501_CR18","first-page":"60","volume":"25","author":"S Stevens","year":"2012","unstructured":"Stevens S, Gilbert C, Astbury N. How to measure intraocular pressure: applanation tonometry. Commun Eye Health. 2012;25(79\u201380):60.","journal-title":"Commun Eye Health"},{"issue":"5","key":"501_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/10799893.2020.1818094","volume":"41","author":"YJ Huang","year":"2021","unstructured":"Huang YJ, Galen K, Zweifel B, Brooks LR, Wright AD. Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists. J Recept Signal Transduct Res. 2021;41(5):425\u201333.","journal-title":"J Recept Signal Transduct Res"},{"key":"501_CR20","doi-asserted-by":"crossref","unstructured":"Poola N, Due B, Wright D, Brooks LR, Zaman F. Pharmacokinetics and pharmacodynamics of repository corticotropin injection compared with synthetic ACTH1\u201324 depot and methylprednisolone in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(4):502-15.","DOI":"10.1002\/cpdd.1020"},{"issue":"7","key":"501_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cpdd.894","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang X, Pham L, Poola N, Brooks LR, Due B. Comparison of steroidogenic exposure following the administration of repository corticotropin injection with a synthetic ACTH1-24 depot and methylprednisolone in healthy subjects. Clin Pharmacol Drug Dev. 2021;10(7):777\u201388.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00501-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00501-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00501-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T17:56:19Z","timestamp":1652810179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00501-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00501-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}